BACKGROUND: Clinic-based effectiveness studies of sleep-disordered breathing (SDB) treatment in reducing BP in resistant hypertension (RHTN) vs non-RHTN are sparse. We hypothesize that CPAP use in SDB reduces BP significantly in RHTN and non-RHTN in a large clinic-based cohort.
Hypertension (HTN), including resistant hypertension (RHTN), represents an enormous economic burden to society 1, 2 with an estimated 3% to 30% of patients with HTN also suffering from RHTN. 3, 4 RHTN is defined as BP that remains above goal (140/90 mm Hg) despite simultaneous use of three classes of antihypertensive agents including a diuretic, or controlled BP with use of at least four antihypertensive medication classes. 5 In the past decade, while the prevalence of HTN has remained stable, there has been an approximate doubling of RHTN prevalence. 6 Given the challenges and complexities in classification of true RHTN, "apparent" RHTN has become an increasingly used term and therefore in this manuscript, RHTN implicitly refers to apparent RHTN. 7 Considering the key role of sleepdisordered breathing (SDB) in the etiopathogenesis of HTN, increase in RHTN is likely attributable to the increased prevalence in SDB. As HTN severity increases, the risks for cardiovascular events, stroke, and death worsen compared with individuals with controlled HTN. 8, 9 Clinical data suggest an association between SDB and RHTN. 10 Potential mechanisms include endothelial dysfunction 11 and activation of the renin-angiotensinaldosterone system. [12] [13] [14] [15] Additionally, increased sympathetic activity, changes in autonomic cardiovascular modulation, increased systemic inflammation and increased chemo reflex drive, and increased rostral edema contribute to increases in BP, including rises that are refractory to standard medication treatment. [16] [17] [18] [19] Randomized clinical trials have demonstrated modest antihypertensive benefits of treatment of SDB with CPAP, with mild reductions in BP of 3 to 5 mm Hg 20, 21 compared with more substantive reductions in RHTN, namely 7 to 10 mm Hg. 22 Notwithstanding the vast interventional trial data published on SDB and HTN, relatively fewer randomized studies [23] [24] [25] have investigated the effect of CPAP on control of BP in patients with OSA and RHTN, and none have examined the effect of CPAP in real-world clinical practice settings. 22, 26, 27 The limited data available in the "real-world" clinical practice setting suggests a reduction in mean arterial pressure (MAP) in a small sample of patients with resistant hypertension, and a negligible effect on hypertensive patients with controlled BP. 28 We, therefore, chose to leverage an existing large, clinicbased cohort to investigate the effect of CPAP on BP in patients with RHTN vs non-RHTN presenting to a large tertiary care sleep medicine clinic. We hypothesize that CPAP use in SDB will reduce BP significantly in RHTN and non-RHTN, and the effect will be more pronounced in RHTN, even after consideration of confounders. Additionally, given data implicating the preferential role of rostral neck edema specifically in RHTN compared with HTN, 19 we anticipate that neck circumference used in place of BMI will more accurately characterize the anthropometric risk in RHTN.
Materials and Methods

Study Procedures
Study Sample: Electronic medical record (EMR) data extraction was performed for patients $ 18 years of age presenting for outpatient visits in the Cleveland Clinic Sleep Disorders Center (SDC) from January 7, 2010, to July 16, 2013 . Patient confirmation of HTN and SDB was based on physician diagnosis and self-reported use of CPAP therapy for SDB collected through the Cleveland Clinic's Knowledge Program (KP), an electronic system for systematically collecting patient-reported outcomes at outpatient clinic visits. Patients with the most common causes of secondary HTN including chronic renal disease, primary hyperaldosteronism, Cushing syndrome, renal artery stenosis, or a combination were excluded. Comorbid conditions were extracted based upon physician completion or ICD billing code.
We defined the baseline visit as the last SDC visit in which the patient indicated that there had been no CPAP usage. The date of CPAP initiation was based on change to the affirmative from the baseline clinic visit for a patient-reported question regarding CPAP therapy collected by the KP. Baseline demographic and clinical data included age, sex, race, history of diabetes, and history of cardiac comorbidities (ie, cardiovascular disease, peripheral vascular disease, coronary heart disease, heart failure, or stroke). Sleep study data including the apnea-hypopnea index (AHI) were obtained from polysomnography and combined with EMR data to obtain baseline BMI (kg/m 2 ) and neck circumference (cm). Antihypertensive medication usage (indicated as active in the EMR), BP, and selfreported CPAP adherence were extracted for the baseline visit and all subsequent SDC visits in the following year. Antihypertensive medications were grouped as follows: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, b-blockers, dihydropyridine or nondihydropyridine calcium channel blockers, central a agonists, direct vasodilators, diuretics, peripheral a blockers, and renin inhibitors. Combination antihypertensive medications were allocated to multiple discrete classes based on components. We defined baseline RHTN as per the American Heart Association scientific statement 5 ; that is, BP that remains above goal (140/90 mm Hg) despite simultaneous use of three classes of antihypertensive agents including a diuretic, or controlled BP with use of at least four antihypertensive medication classes. Patients without RHTN comprised the non-RHTN group. The study was approved by Institutional Review Board of the Cleveland Clinic (number 12-967).
Polysomnography: Polysomnography was performed according to standard guidelines 29 using a Nihon Kohden system, version 8 (Nihon Kohden Corporation). Hypopneas were defined as $ 50% reduction of airflow in the nasal pressure channel for $ 10 s resulting in an arousal or $ 3% oxygen desaturation. 29 The recording montage included EEG (F3-M2, C3-M2, O1-M2, F4-M1, C4-M1, O2-M1), bilateral electrooculography, submental and bilateral anterior tibialis electromyography, position sensor, ECG, thoracic and abdominal respiratory inductance plethysmography, and finger pulse oximetry. Nasal airflow and nasal pressure was measured using an oronasal thermistor and nasal cannula respectively.
BP Measurement: BP measurements were obtained in the outpatient setting in the SDC by a medical assistant using an automatic cuff according to standard clinical procedure, that is, in the sitting position with the patient relaxed, legs uncrossed, and the arm maintained at the level of the heart (Automated Dynamat, Dinamap Procare Monitor; GE Medical System).
KP System: The Cleveland Clinic KP 30 is an independent electronic outcomes measurement and archival system that is also embedded within the EMR. Pertinent health status measures in the SDC measurement ensemble include questions regarding the usage of CPAP and the self-report of the number of days and hours of usage. The Centers for Medicare and Medicaid Services define CPAP adherence as $ 5 d/wk and $ 4 h/d of self-reported CPAP use. 31 Statistical Analysis: We calculated descriptive statistics for each baseline variable stratified by HTN group. We tested for differences in baseline variables between the RHTN and non-RHTN groups using Wilcoxon (continuous variables) and Fisher exact tests (categorical variables).
Primary Analysis: We examined the association between CPAP therapy and change in BP using linear mixed-effects models that account for the varying numbers of follow-up days between patients when analyzing BP measurements. The models included BP outcome variables such as systolic BP (SBP), diastolic BP (DBP), or MAP ([2 Â DBP) þ SBP]/3) and predictors included an indicator for pre/ post-CPAP initiation, HTN group, and other clinically relevant baseline variables including age, sex, race, BMI, cardiac, and diabetes history. We included normally distributed subject-specific random effects at the patient level to account for correlation between repeated measurements within the same patient, considering both random intercepts and slopes specifications. Fixed effects were included for all other variables. To test whether the difference in BP from baseline averaged over the follow-up period differed between the RHTN and non-RHTN groups, we tested a fixed-effect interaction term between pre/post-CPAP and HTN group to address the primary hypothesis. We also tested a fixed effect interaction term between pre/post-CPAP and controlled and uncontrolled BP in the RHTN group to assess for differential effects of CPAP on BP outcomes in these groups.
Secondary Analysis: There are data suggesting that neck size is a predictor for SDB 32 and may serve as a surrogate for rostral fluid displacement which bears biologic plausibility in the pathogenesis of SDB and RHTN. 19 We, therefore, considered the impact of substituting neck size for BMI in the multivariable model to examine for superiority of fit. We noted changes in model coefficients and significance and compared model fit using Akaike Information Criteria (AIC) with a better fitting model defined as two or more units lower than the comparison model. 33 As AHIs were not available for the patients who underwent sleep studies at facilities other than Cleveland Clinic, we examined models including AHI in the subset of patients with available data. We performed sensitivity analysis to assess the robustness of the primary analysis in terms of CPAP adherence only on patients who selfreported as CPAP adherent, which included baseline visits for all patients with at least one visit reporting adherence data, but only considered follow-up visits when adherence was reported. All statistical analyses were performed using R, version 3.1.1, 34 and P values # .05 were considered statistically significant.
Results
Baseline Characteristics
We analyzed 894 of 1,000 (89%) eligible patients with HTN who had complete data from their visit at the Cleveland Clinic SDC during the study period (Table 1) . Generally, patients with missing RHTN status had similar demographic characteristics to those with complete data but tended to be slightly younger (49 AE 14 years, P < .001); have increased neck size, 42 (AE 5) cm; less history of diabetes, 88 (86%) and cardiac comorbidities, 93 (91%); and higher MAP, 99 (AE 11) mm Hg, and DBP, 81 (AE 10) mm Hg. Among patients with complete and available RHTN status, 130 (15%) were RHTN positive at baseline (98 patients with controlled BP [75.4%] and 32 [24. 6%] with noncontrolled BP) and the remaining 764 (85%) classified as non-RHTN. The mean age and BMI were significantly higher in the RHTN group compared with the non-RHTN group (P ¼ .02 and P ¼ .007, respectively) and the groups were balanced in terms of sex. A higher but nonsignificant percentage of African Americans were observed in the RHTN group compared with the non-RHTN group. The MAP and SBP at baseline were higher in the RHTN than the non-RHTN group (P < .01), whereas no significant difference was found for DBP.
Of the full dataset, 728 (81.4%) met the Centers for Medicare and Medicaid Services definition for selfreported CPAP adherence for at least one follow-up visit. Most demographic characteristics were similar between the adherent and nonadherent groups, although adherent patients were older, had higher AHI, were more likely to have a history of cardiac comorbidities, and had slightly lower MAP and DBP.
CPAP Effect on Change in BP Indexes in RHTN and Non-RHTN
Primary Analysis: A small and nonstatistically significant interaction term was observed between post-CPAP and RHTN in all models indicating reduction in BP was not different between the RHTN and non-RHTN groups. Thus, this term was excluded from the final model.
In fully adjusted models, in the year following CPAP initiation, there was a significant decrease in SBP (3.08 mm Hg; 95% CI, 1.79, 4.37), DBP (2.28, 95% CI, 1.56, 3), and MAP (2.54 mm Hg; 95% CI, 1.73, 3.36). This improvement did not differ based on RHTN status, but patients with RHTN had higher BP indices overall (all P < .001) in the adjusted models, most notably for SBP (6.90 mm Hg; 95% CI, 3.84, 9.95) both before and after CPAP initiation (Fig 1) . Note that although the CIs of the predicted SBP overlap between non-RHTN and RHTN groups, the difference between groups is significantly different from zero (P < .001), as is also the case for MAP and DBP (Table 2) . Patients with cardiac history had lower BP profiles and patients with diabetes and increasing age were associated with lower MAP and DBP. The interaction term of pre/post-CPAP and controlled and uncontrolled BP groups of RHTN was not statistically significant, thereby indicating no differential impact of CPAP on BP outcomes between the groups.
Secondary Analyses: Substituting neck size for BMI (Table 3) yielded a better fitting model, as measured by AIC ( Additionally, in the CPAP adherent group, those with RHTN at baseline and at follow-up had a higher BP overall, most notably for SBP (5.79 mm Hg; 95% CI, 2.54, 9.04), consistent with the overall cohort findings (Table 5 ).
Discussion
The most striking observation emerging from our clinic-based 1-year follow-up large-scale patient study was a similar improvement in SBP, DBP, and MAP following CPAP initiation regardless of RHTN status. Additionally, we observed a pronounced reduction in SBP, responsible for driving the concordant improvement of MAP. The overall findings of BP improvements persisted even after exclusion of patients not adherent to CPAP. Data also suggested that neck size may provide a better sense of risk physiology compared with BMI.
While we expected to find an overall improvement in BP profiles in those with HTN and non-RHTN following CPAP adherence, we unexpectedly observed no differential BP improvement between RHTN and non-RHTN groups, contrasting a previous retrospective study demonstrating a significant BP reduction among non-RHTN patients, but not patients with RHTN. 28 Possible reasons for observed differences include a higher number of women with high cardiovascular risk in our study compared with the mostly male cohort in the previous study, highlighting the potential for 26 While we also observed a reduction in MAP of similar magnitude in response to CPAP, this reduction appears to be predominantly driven by improvement in SBP. Differences in the mode of BP ascertainment vs differences in study design, that is, use of a pragmatic vs eligibility-driven approach may account for differences in findings. 26 The current findings are noteworthy as these involve a large cohort and add to the existing small body of evidence that a reduction in BP occurs in both RHTN and non-RHTN among patients in a clinical setting. Our finding of CPAP benefit in terms of SBP are important as elevated SBP has been consistently associated with adverse implications including heart failure risk in elderly patients having a SBP as low as < 115 mm Hg. 35 Control of SBP leads to reduction in mortality, stroke, and heart failure events. 36, 37 Even modest reductions in BP of 2 to 3 mm Hg can reduce coronary artery disease by 4% to 5% and stroke by 6% to 8%. 38 These effectiveness data underscore the importance of SDB management in RHTN and non-RHTN populations to improve BP to mitigate long-term adverse cardiovascular consequences.
It is interesting to note that patients with cardiac history had lower BP profiles and patients with diabetes had lower MAP and DBP. A potential explanation for this observation is that these patients may have closer followup and may receive more intensive medical management compared with those without cardiac comorbidity. It is recognized that isolated systolic hypertension occurs with increasing age, 39 therefore, the relatively lower diastolic and mean arterial systolic pressures observed relative to systolic pressure are anticipated.
The role of rostral neck edema in heart failure and particularly in RHTN is becoming increasingly recognized. Neck circumference has been shown to be independently associated with coexistence of HTN in SDB 40 and may represent greater rostral edema shift in RHTN compared with HTN. 19 RHTN and its association with hyperaldosteronism 41 -mediated fluid retention can potentially cause more rostral edema. Results from multivariable model including only compliant patients. See Table 1 legend for expansion of abbreviations.
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Our model revealed neck size to be a better anthropometric measure than BMI, supporting the concept that in hypertensive patients, rostral fluid displacement participates in the pathogenesis of SDB by narrowing the upper airway, thereby rendering susceptibility to a collapsed airway during sleep.
The large sample size, long follow-up duration up to 1 year and reduction in BP noted in a real-world population were some of the major strengths of our study. Limitations include the retrospective design and potential selection bias. We relied on self-reported PAP adherence data, classifying 81% of our subjects as adherent, which is comparable to other large cohorts. 42 While objective adherence data were not available for the current study, we previously reported a significant correlation between objective and self-reported adherence in patients with SDB treated in our center. 43 The dose of antihypertensive pharmacotherapy and medication adherence could not be ascertained which may have led to misattribution of true resistant hypertension in the actual setting of pseudoresistance and thereby could possibly have partially explained the lack of BP difference in terms of PAP response between the groups. Ambulatory BP measurements were not obtained, however, we have previously shown that resting BP values moderately correlate with the ambulatory BP values 44 and thus any systematic BP measurement, while affecting study data, would not have affected the generalizability of findings.
Conclusions
In conclusion, CPAP therapy reduced BP parameters in a large, clinic-based population of patients with RHTN and those who were non-RHTN by a similar extent which has important implications for clinicians managing HTN populations by providing guidance in terms of anticipated BP response from CPAP intervention in the real-world setting in patients with SDB. Future studies exploring effects of CPAP therapy on other outcomes in HTN populations are required.
